• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4640408)   Today's Articles (198)   Subscriber (50360)
For: Yang H, Yu X, An Z. Cutaneous Toxicity Associated With Enfortumab Vedotin: A Real-Word Study Leveraging U.S. Food and Drug Administration Adverse Event Reporting System. Front Oncol 2022;11:801199. [PMID: 35127510 PMCID: PMC8807512 DOI: 10.3389/fonc.2021.801199] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2021] [Accepted: 12/22/2021] [Indexed: 12/03/2022]  Open
Number Cited by Other Article(s)
1
Yu M, Zhou L, Cao M, Ji C, Zheng Y. Post-marketing drug safety surveillance of enfortumab vedotin: an observational pharmacovigilance study based on a real-world database. Front Immunol 2024;15:1397692. [PMID: 39234238 PMCID: PMC11372787 DOI: 10.3389/fimmu.2024.1397692] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2024] [Accepted: 07/29/2024] [Indexed: 09/06/2024]  Open
2
Wang X, Yang H, An Z. Tacrolimus related diabetic ketoacidosis and hyperglycaemic hyperosmolar nonketotic syndrome: an observational, retrospective, pharmacovigilance study. Expert Opin Drug Saf 2024:1-6. [PMID: 39149847 DOI: 10.1080/14740338.2024.2393278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2024] [Revised: 07/09/2024] [Accepted: 07/11/2024] [Indexed: 08/17/2024]
3
Daher R, Ruplin A, Gupta S, Spiess PE, Kamat AM, Cigliola A, Tateo V, Mercinelli C, Grivas P, Necchi A. The spectrum of cutaneous toxicities related to novel genitourinary cancer therapies. Crit Rev Oncol Hematol 2024;200:104420. [PMID: 38906514 DOI: 10.1016/j.critrevonc.2024.104420] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2024] [Revised: 04/29/2024] [Accepted: 06/07/2024] [Indexed: 06/23/2024]  Open
4
Yang H, Ding Z, An Z, Zhao Y, Lu H. Immune checkpoint inhibitor related myositis: an observational, retrospective, pharmacovigilance study. Expert Opin Drug Saf 2024:1-6. [PMID: 38629402 DOI: 10.1080/14740338.2024.2343023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2023] [Accepted: 01/26/2024] [Indexed: 04/25/2024]
5
Wang G, Wang J, Du R, Wang Y, Li Z. Toxicity Spectrum of Anti-GD2 Immunotherapy: A Real-World Study Leveraging the US Food and Drug Administration Adverse Event Reporting System. Paediatr Drugs 2024;26:175-185. [PMID: 38153627 DOI: 10.1007/s40272-023-00613-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 12/08/2023] [Indexed: 12/29/2023]
6
Yang H, Ding Z, An Z. Urinary tract infection following the use of BTK inhibitors: a real-world analysis of post-marketing surveillance data. Expert Opin Drug Saf 2024;23:333-338. [PMID: 37609933 DOI: 10.1080/14740338.2023.2251376] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2023] [Revised: 07/27/2023] [Accepted: 08/09/2023] [Indexed: 08/24/2023]
7
Haynes D, Morgan EE, Chu EY. Cutaneous adverse reactions resulting from targeted cancer therapies: histopathologic and clinical findings. Hum Pathol 2023;140:129-143. [PMID: 37146945 DOI: 10.1016/j.humpath.2023.04.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/03/2023] [Revised: 04/19/2023] [Accepted: 04/26/2023] [Indexed: 05/07/2023]
8
Li D, Gou J, Zhu J, Zhang T, Liu F, Zhang D, Dai L, Li W, Liu Q, Qin C, Du Q, Liu S. Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database. Front Pharmacol 2023;14:1117391. [PMID: 37081961 PMCID: PMC10110972 DOI: 10.3389/fphar.2023.1117391] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2022] [Accepted: 03/23/2023] [Indexed: 04/07/2023]  Open
9
Hasui K, Kawakami Y, Miyake T, Hirai Y, Nomura H, Edamura K, Araki M, Morizane S. Cutaneous toxicity with suprabasal blisters and dyskeratosis following administration of enfortumab vedotin. J Dermatol 2022;50:e115-e116. [PMID: 36412280 DOI: 10.1111/1346-8138.16646] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2022] [Revised: 10/11/2022] [Accepted: 10/30/2022] [Indexed: 11/23/2022]
10
Xia S, Zhao YC, Guo L, Gong H, Wang YK, Ma R, Zhang BK, Sheng Y, Sarangdhar M, Noguchi Y, Yan M. Do antibody-drug conjugates increase the risk of sepsis in cancer patients? A pharmacovigilance study. Front Pharmacol 2022;13:967017. [PMID: 36467034 PMCID: PMC9710632 DOI: 10.3389/fphar.2022.967017] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2022] [Accepted: 10/17/2022] [Indexed: 04/02/2024]  Open
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA